CG Oncology, Inc. Common stock
CGON
$61.89
-3.67%
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company singularly focused on developing and commercializing its lead product candidate, cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy for patients with non-muscle invasive bladder cancer (NMIBC). The company is positioned as a potential first-mover in a significant unmet medical need, specifically targeting high-risk BCG-unresponsive NMIBC, a market with limited treatment options. The current investor narrative is overwhelmingly driven by the binary clinical and regulatory catalysts for its pivotal Phase 3 trials, with recent stock volatility reflecting the market's anticipation of data readouts and the path to a potential near-term Biologics License Application (BLA) submission, which could establish it as a new standard of care.…
CGON
CG Oncology, Inc. Common stock
$61.89
CGON 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CG Oncology, Inc. Common stock's 12-month outlook, with a consensus price target around $80.46 and implied upside of +30.0% versus the current price.
Average Target
$80.46
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$50 - $80
Analyst target range
Analyst sentiment is uniformly and strongly bullish, with 6 firms providing coverage and all recent institutional ratings being Buy or Overweight equivalents, including reaffirmations from firms like HC Wainwright, Truist Securities, and RBC Capital throughout 2025 and 2026. While a precise consensus price target is not provided in the data, the sustained bullish actions and lack of any Sell or Hold ratings indicate strong institutional conviction in the company's clinical trajectory. The absence of a wide target range in the data suggests analyst views are clustered, reflecting shared optimism about the upcoming Phase 3 data catalysts and commercial launch potential for cretostimogene. This high-conviction, low-coverage profile is typical for a emerging biotech and implies that positive clinical data could lead to significant target price increases and further institutional adoption.
Bulls vs Bears: CGON Investment Factors
The bull case, driven by unanimous analyst conviction and the potential for a blockbuster drug in a large unmet market, is currently stronger, as evidenced by the stock's powerful 164% yearly uptrend and robust balance sheet. However, the bear case presents a formidable counter-argument centered on an extreme, binary-risk valuation that demands flawless execution. The single most important tension in the investment debate is the disconnect between the current astronomical valuation (PS of 794.5x) and the binary, all-or-nothing nature of the upcoming Phase 3 data readouts. The stock's future trajectory will be determined almost entirely by the success or failure of these clinical trials.
Bullish
- Unanimous Analyst Conviction: All 6 covering analysts have Buy/Overweight ratings, indicating high institutional conviction in the upcoming Phase 3 data and commercial potential. This consensus suggests a high probability of positive catalysts driving the stock higher.
- Strong Balance Sheet & Liquidity: The company has a robust financial position with a current ratio of 24.63 and a negligible debt-to-equity ratio of 0.0093. It recently raised $99 million in Q4 2025, providing ample runway to fund pivotal trials and a potential commercial launch.
- Dominant Technical Momentum: The stock is in a powerful uptrend, gaining 164% over the past year and trading at 83% of its 52-week high of $75.50. Its beta of 0.417 indicates it has been less volatile than the market during this rally, suggesting strong underlying support.
- First-Mover in Large Unmet Need: Cretostimogene targets high-risk BCG-unresponsive NMIBC, a market with limited treatment options. Success in its pivotal Phase 3 trials could establish it as a new standard of care, justifying its speculative valuation.
Bearish
- Extreme Pre-Revenue Valuation: The stock trades at astronomical valuation multiples: a trailing PS of 794.5x and an EV/Sales of 998.7x. This prices in near-perfect clinical and commercial success, leaving no margin for error and high risk of multiple compression.
- Binary Clinical & Regulatory Risk: The entire investment thesis hinges on positive Phase 3 data and subsequent FDA approval for a single asset, cretostimogene. Any clinical setback or regulatory delay could collapse the stock price, as seen with other single-asset biotechs.
- Deeply Unprofitable with High Burn: The company is deeply unprofitable, with a Q4 2025 net loss of $41.3 million, a gross margin of -25.5%, and a TTM free cash flow burn of -$132.5 million. Losses are widening as trials progress, requiring continued capital raises.
- Vulnerable to Profit-Taking After Rally: Trading near its 52-week high after a 164% surge, the stock is susceptible to a sharp pullback on any negative news or market-wide risk-off sentiment. The recent 1-month decline of -1.11% underperforming the SPY by -6.71% may signal exhaustion.
CGON Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 164.02% gain over the past year. As of the latest close at $66.93, the price is trading near the upper end of its 52-week range ($23.65 to $75.50), approximately 83% of the way to its high, indicating strong momentum but also potential vulnerability to profit-taking after such an extended rally. Recent momentum shows signs of consolidation; the stock is down 1.11% over the past month, diverging from its strong 3-month gain of 29.96%, suggesting a pause or pullback within the larger uptrend as it digests gains. This short-term weakness is further highlighted by a negative 1-month relative strength of -6.71 versus the SPY. Key technical levels are clearly defined, with immediate support at the 52-week low of $23.65 and formidable resistance at the 52-week high of $75.50. A breakout above $75.50 would signal a resumption of the primary bull trend, while a sustained break below key moving averages would suggest a deeper correction. The stock's beta of 0.417 indicates it has been significantly less volatile than the broader market during this period, which is unusual for a clinical-stage biotech and may reflect a high degree of institutional conviction limiting downside moves.
Beta
0.42
0.42x market volatility
Max Drawdown
-25.3%
Largest decline past year
52-Week Range
$24-$76
Price range past year
Annual Return
+143.3%
Cumulative gain past year
| Period | CGON Return | S&P 500 |
|---|---|---|
| 1m | -9.9% | +5.1% |
| 3m | +8.6% | +8.3% |
| 6m | +38.0% | +10.4% |
| 1y | +143.3% | +29.6% |
| ytd | +48.1% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CGON Fundamental Analysis
As a pre-revenue clinical-stage company, CGON's financials reflect heavy investment in R&D. Revenue is minimal and erratic, with the latest quarter (Q4 2025) showing $2.32 million, representing a modest 4.09% year-over-year growth, but this figure is not indicative of commercial traction as it stems from collaboration agreements. The company is deeply unprofitable, reporting a net loss of $41.31 million for Q4 2025 and a gross margin of -25.5%, which is negative due to costs exceeding its minimal collaborative revenue. Losses have widened sequentially from $31.80 million in Q4 2024, consistent with the increased expenses of conducting late-stage pivotal trials. The balance sheet, however, remains robust to fund operations. The company exhibits exceptional liquidity with a current ratio of 24.63 and a minimal debt-to-equity ratio of 0.0093, indicating virtually no financial leverage. Trailing twelve-month free cash flow is deeply negative at -$132.48 million, which is expected, but the company bolstered its cash position significantly through equity issuance, raising $99.07 million from financing activities in Q4 2025 alone, ending the period with $32.49 million in cash.
Quarterly Revenue
$2322000.0B
2025-12
Revenue YoY Growth
+4.09%
YoY Comparison
Gross Margin
-0.25%
Latest Quarter
Free Cash Flow
$-132480000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CGON Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio. The trailing PS ratio is an astronomical 794.47x, while the Enterprise Value-to-Sales (EV/Sales) is even higher at 998.72x, reflecting a valuation entirely predicated on future commercial potential rather than current financials. A direct peer comparison to industry averages is not meaningful due to the company's pre-commercial status; such extreme multiples are common for late-stage biotechs with blockbuster potential and are not compared to profitable sector averages. Historically, the stock's own valuation has soared; the current PS ratio of 794.47x is dramatically higher than its PS ratio of 1,382.27x at the end of 2025, indicating some multiple compression even as the stock price has risen, due to the expectation of future sales growth. Trading near the upper end of its own historical valuation range suggests the market has already priced in a high probability of clinical success and significant future revenue, leaving little room for error.
PE
-19.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -74x~-12x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-20.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and inherent to CGON's stage. The company is pre-revenue with a negative gross margin of -25.5% and a net loss of $41.3 million in its latest quarter, reflecting the high cost of running Phase 3 trials. Its TTM free cash flow burn of -$132.5 million, though funded by recent equity raises, underscores a dependency on capital markets. The entire business model is a single-point-of-failure, concentrated 100% on the success of cretostimogene, making its financials highly volatile and binary.
Market & Competitive Risks are dominated by valuation compression. Trading at a PS ratio of 794.5x, the stock is priced for perfection. Any disappointment in trial efficacy, safety, or commercial uptake could trigger a violent de-rating. While the beta of 0.417 suggests lower-than-market volatility historically, this is atypical for a clinical-stage biotech and may not hold during a negative catalyst. Competitive threats from other late-stage therapies for BCG-unresponsive NMIBC could also erode its first-mover advantage and projected market share.
Worst-Case Scenario involves the failure of the lead asset in Phase 3 trials or a regulatory rejection. In this scenario, the company's valuation would collapse to near its cash value, as the pipeline would be essentially worthless. A realistic downside target aligns with the 52-week low of $23.65, representing a potential loss of approximately -65% from the current price of $66.93. Given the binary nature of the stock, a drawdown of this magnitude is a plausible, albeit low-probability, risk that investors must accept.
